Figure 6
From: Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
(A) cHcAb6 binds to cells expressing the canine FcγRI receptor. MDCK cells transiently expressing FcγRI were stained with cNb6, and bound cHcAb6 was detected using anti-Fc-750 antibody by flow cytometry. Canine IgG and cells stained with secondary Ab only were used as controls. (B) cHcAb6 induces IFN-γ expression from PBMCs after CD3 stimulation. CPBMCs were stimulated with 1 μg/mL of anti-CD3 antibody in the presence or absence of 100 nM of cHcAb6. After 72 h, IFN-γ expression was quantified using TaqMan assays. HRPT1 was used as endogenous control, and expression levels of IFN-γ were normalized to CD3 stimulated PBMCs. All experiments were performed in triplicates.
